Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | Journal of Hematology & Oncology

Fig. 6

From: The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

Fig. 6

Therapeutic effectiveness of targeting the PPI of Gαh/PLC-δ1 by Myr-PLC-δ1 peptide in the orthotropic mouse model of breast cancer. a and b The luminescence intensity of luciferase-expressing MDA-MB-231 cells on weeks 1 and 4 after the orthotropic transplantation into mammary fat pads mice (a). Mice (n = 5) were treated without [PBS containing 0.1% TFA (Mock)] or with CTL or Myr-PLC-δ1 peptide on week 1. b Luminescence intensities of the total flux of protons in the metastatic sites and primary tumors in each group were presented as the median ± SD. c The representative luminescent images (upper panel) and IHC staining images (middle and lower panels) of lungs from each group at the endpoint. d Quantitation of the lung colonies in c. e Size and weight of primary tumors obtained from each group on week 4. The tumor weights are presented as the median ± SD. In b, d, and e, significant differences were analyzed by one-way ANOVA using Tukey’s test

Back to article page